Latest Regulatory News

Page 264 of 637
The Star Entertainment Group reported a challenging FY25 with a $471.5 million statutory net loss and a $77.1 million EBITDA loss before significant items, driven by regulatory reforms and market share declines. The group secured a $300 million strategic investment to support its turnaround efforts amid ongoing legal and licensing uncertainties.
Victor Sage
Victor Sage
29 Aug 2025
Amaero Ltd has launched a $3 million Share Purchase Plan offering eligible shareholders in Australia and New Zealand the chance to buy new shares at $0.40 each, matching a recent placement price. The offer opens on 29 August and closes on 19 September 2025.
Victor Sage
Victor Sage
29 Aug 2025
The Star Entertainment Group reported a statutory net loss of $471.5 million for FY25, impacted by regulatory reforms and remediation costs, while securing a $300 million strategic investment to bolster liquidity.
Victor Sage
Victor Sage
29 Aug 2025
Gladiator Resources has initiated the process to list on the US OTC Markets, aiming to enhance visibility and liquidity among North American investors as part of its rare earth elements growth strategy.
Maxwell Dee
Maxwell Dee
29 Aug 2025
The Star Entertainment Group reported a $471.5 million net loss for FY25, marking a 72% improvement from the prior year but underscored by ongoing regulatory challenges and a complex joint venture exit.
Victor Sage
Victor Sage
29 Aug 2025
Broken Hill Mines Limited reported a $2.42 million loss for FY2025 amid a transformative acquisition of Broken Hill Mines Holdings Pty Ltd and a $20 million capital raise, marking its relisting on the ASX under the code BHM.
Maxwell Dee
Maxwell Dee
29 Aug 2025
Acrux Ltd reported a 44% revenue decline and a modest increase in net loss for FY25, while expanding its US topical generics portfolio and entering the Saudi Arabian market. The company signals a strategic pivot amid intensifying competition and lower returns.
Victor Sage
Victor Sage
29 Aug 2025
Cluey Ltd reported a significantly reduced loss for FY25 alongside an 11% increase in new students and achieved positive operating cash flow in Q4, signaling progress in its path to profitability.
Victor Sage
Victor Sage
29 Aug 2025
Next Science Limited reported a 7% revenue decline and a 20% reduction in net loss for H1 2025, alongside a major $50 million asset sale agreement with OSARTIS GmbH. The transaction, approved by shareholders, signals a strategic pivot for the biofilm-focused medical device company.
Ada Torres
Ada Torres
29 Aug 2025
Tryptamine Therapeutics reported a $5.33 million loss for FY25 while progressing key clinical trials of its psychedelic therapies and strengthening its leadership team. The company secured $6 million in funding and launched a world-first trial targeting Binge Eating Disorder.
Ada Torres
Ada Torres
29 Aug 2025
Orbital Corporation Limited posted a $4.3 million net loss for FY25, reflecting a revenue decline amid production transitions. The company secured a $3 million capital raise to support new UAV engine development and expand its global footprint.
Victor Sage
Victor Sage
29 Aug 2025
LTR Pharma’s FY25 results reveal a transformative year highlighted by SPONTAN’s rapid absorption and strategic partnerships that pave the way for US market entry.
Ada Torres
Ada Torres
29 Aug 2025